MYGN - Myriad Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.99
-0.07 (-0.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close26.06
Open25.88
Bid0.00 x 1200
Ask0.00 x 1300
Day's Range25.64 - 26.14
52 Week Range22.07 - 50.44
Volume282,409
Avg. Volume1,001,519
Market Cap1.907B
Beta (3Y Monthly)1.38
PE Ratio (TTM)92.49
EPS (TTM)0.28
Earnings DateAug 19, 2019 - Aug 23, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.91
Trade prices are not sourced from all markets
  • Barrons.com8 days ago

    Myriad Genetics Stock Is Falling as Enthusiasm Wanes

    Cowen analysts said their enthusiasm for the stock had been shaken by the company’s past two financial updates.

  • Here’s What Hedge Funds Think About Myriad Genetics, Inc. (MYGN)
    Insider Monkey12 days ago

    Here’s What Hedge Funds Think About Myriad Genetics, Inc. (MYGN)

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues
    Zacks15 days ago

    Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues

    Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.

  • GlobeNewswire20 days ago

    Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

    SALT LAKE CITY, June 27, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of results from a large study that.

  • GlobeNewswire22 days ago

    Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer.

    Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the first comprehensive cost-effectiveness analysis of the EndoPredict® test compared to other breast cancer assays. The key finding is that EndoPredict test was more than twice as cost effective as Oncotype DX®. Breast cancer is the most common cancer in women worldwide.

  • GlobeNewswire22 days ago

    Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer

    Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the first comprehensive cost-effectiveness analysis of the EndoPredict® test compared to other breast cancer assays. The key finding is that EndoPredict test was more than twice as cost effective as Oncotype DX®. Breast cancer is the most common cancer in women worldwide.

  • Read This Before Buying Myriad Genetics, Inc. (NASDAQ:MYGN) Shares
    Simply Wall St.27 days ago

    Read This Before Buying Myriad Genetics, Inc. (NASDAQ:MYGN) Shares

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • GlobeNewswire28 days ago

    Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan

    SALT LAKE CITY, June 19, 2019 -- Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced the Japanese Ministry of.

  • Markit29 days ago

    See what the IHS Markit Score report has to say about Myriad Genetics Inc.

    Myriad Genetics Inc NASDAQ/NGS:MYGNView full report here! Summary * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for MYGN with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MYGN had net inflows of $2.20 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Corporations Shouldn't Be Able to Patent Your DNA
    Bloomberglast month

    Corporations Shouldn't Be Able to Patent Your DNA

    (Bloomberg Opinion) -- The practice of patenting genes, once banned by the Supreme Court, may come back soon despite a measure of horror the very idea once inspired. Author Michael Crichton warned of the evils of gene patents in his 2006 novel “Next” and, more directly, in a 2007 New York Times commentary piece.Crichton’s concern about giving exclusive legal rights to the use of information about human bodies was a matter of principle: “You can’t patent snow, eagles or gravity, and you shouldn’t be able to patent genes, either. Yet by now one-fifth of the genes in your body are privately owned.”Prominent scientists are now raising objections that the practice will restrict potentially valuable medical research. If one company develops a genetic test for a disease, for example, a patent on the gene involved might prevent scientists at a different institution from seeking possible gene therapies for the disease.The latest battle is taking place in Congress, where a new bill might override a Supreme Court ban from 2013. One prominent critic this time around is Harold Varmus, Nobel laureate and former head of the National Cancer Institute, who argues that the proposed law “would result in a quagmire of patent claims and legal impediments to the normal scientific exchange.”As recently as the late 20th century, the patenting of genes was fairly uncontroversial. At that time, explains Robert Cook-Deegan, a professor in the School for the Future of Innovation in Society at Arizona State University, it was understood that granting a patent on use of a particular gene was equivalent to a patent on a gene-related invention – like a technique for making insulin or human growth hormone from genetically modified organisms.But around the end of the century, genetic testing exploded, and, at least in principle, patent holders who should have rights to a single genetic test were getting broad rights over future research or therapies based on the same gene. Crichton took issue with a genetic test for a deadly inherited condition called Canavan disease. But what finally got the Supreme Court involved was a test for mutations in genes known as BRCA1 and BRCA2, associated with a strong predisposition to breast and ovarian cancer.The company owning those patents, Myriad Genetics, won a race to find the DNA sequence making up the breast cancer gene BRCA1, thus making it possible to test for mutations that conferred breast cancer risk. But like most scientific advances, Myriad’s achievement was intertwined with work of others. Mary-Claire King of the University of Washington, for instance, had done the detective work to recognize that such a gene must exist. In a 1990 paper in Science, she demonstrated that a gene (which she named BRCA1) on Chromosome 17 was being passed through families that were repeatedly stricken with breast or ovarian cancer.The patent gave Myriad so much power that the company was able to charge outside researchers to do clinical trials designed to figure out how well the gene tests worked, and to find a best practice for properly informing women about the meaning of their results. This education is a serious priority for public health because a positive test has motivated some women to have healthy breasts and ovaries removed – which some experts consider too risky for the amount of protection it confers.By the early part of this decade, the ACLU started to protest Myriad’s gene patent, and by 2013, the Supreme Court agreed and the patents were revoked. The result: Myriad stayed in business, other labs started to develop their own tests for breast cancer risk, and the technology advanced. Now breast cancer risk testing can include as many as 28 different genes.  The main downside for genetic research generally has been a lack of clarity about which genetic discoveries are patentable. The proposed legislation under debate in Congress is meant to fix that problem. But by reverting to the pre-2013 situation when there were virtually no restrictions, it goes too far. The bill, if passed, would allow gene patents to curtail research. Gene patenting isn’t the horror that Michael Crichton imagined, but neither is the race for patents the key motivator for genetic breakthroughs.If lawmakers want to help, they should give clarity, not restrictions, on research rights.To contact the author of this story: Faye Flam at fflam1@bloomberg.netTo contact the editor responsible for this story: Philip Gray at philipgray@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Faye Flam is a Bloomberg Opinion columnist. She has written for the Economist, the New York Times, the Washington Post, Psychology Today, Science and other publications. She has a degree in geophysics from the California Institute of Technology.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • Why Is Myriad (MYGN) Down 6.4% Since Last Earnings Report?
    Zackslast month

    Why Is Myriad (MYGN) Down 6.4% Since Last Earnings Report?

    Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • AngioDynamics Divests NAMIC Portfolio to Medline Industries
    Zackslast month

    AngioDynamics Divests NAMIC Portfolio to Medline Industries

    The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.

  • Myriad Genetics Announces Study Results Of myRisk Cancer Test
    Zackslast month

    Myriad Genetics Announces Study Results Of myRisk Cancer Test

    The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.

  • GlobeNewswirelast month

    Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference

    SALT LAKE CITY, June 05, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone,.

  • Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May
    Motley Foollast month

    Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May

    Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.

  • Myriad Genetics' (MYGN) POLO Study Shows Positive Results
    Zackslast month

    Myriad Genetics' (MYGN) POLO Study Shows Positive Results

    Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.

  • GlobeNewswirelast month

    Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology

    SALT LAKE CITY, June 03, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from two.

  • GlobeNewswirelast month

    BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)

    “Our long-standing collaboration with Myriad Genetics Inc. has enabled us to deliver the positive POLO study in pancreatic cancer patients, demonstrating our shared ambition to target precision medicines to the right patients across different cancers,” said Ruth March, Ph.D., senior vice president and head of Precision Medicine, Oncology R&D, AstraZeneca.

  • Is Myriad Genetics, Inc.'s (NASDAQ:MYGN) CEO Salary Justified?
    Simply Wall St.2 months ago

    Is Myriad Genetics, Inc.'s (NASDAQ:MYGN) CEO Salary Justified?

    Mark Capone has been the CEO of Myriad Genetics, Inc. (NASDAQ:MYGN) since 2015. First, this article will compare CEO...

  • Why Should You Hold on to Myriad Genetics (MYGN) Stock?
    Zacks2 months ago

    Why Should You Hold on to Myriad Genetics (MYGN) Stock?

    Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).

  • Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?
    Motley Fool2 months ago

    Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?

    The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.